• Watson Pharmaceuticals Inc., of Parsippany, N.J., said that its subsidiary, Watson Laboratories Inc., filed an abbreviated new drug application with the FDA for Mesalamine delayed-release tablets 1.2 g. The product is a generic version of Lialda, by Shire Development LLC, a division of Shire plc, of Dublin, Ireland.